Amgen

SYMBOL:AMGN|SECTOR:Health Care|DERIVED:CFD
i
Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices are indicative only and not appropriate for trading purposes. Therefore Moneycontrol doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
$
3
3
3
3
.
3
3
7
7
2
2
3.21 (1.19%)

As on 11 Jan, 2023 | 02:29 IST

Trade
Day Range
270.11
274.61
LH
52 Week Range
214.39
296.67
LH
Open271.95
Previous Close270.12
Beta0.33
High274.61
Low270.11
TTM EPS See historical trend   17.96(+8.45% YoY)
52 Week High296.67
52 Week Low214.39
TTM PE See historical trend    15.25(High PE)
Mkt. Cap ($ Billion)146.17
Dividend Yield3.44

Advance Chart

*Delayed by 20 seconds.

MC Technicals

Technical rating
i
This represents current trend.
Click here  for disclaimer.
Trend
Bullish
Moving AveragesBullish
Technical IndicatorsBullish
Moving Averages CrossoversNeutral

Pivot levels

TypeR1R2R3PPS1S2S3
Classic274.25 278.37 281.17271.45 267.33 264.53 260.41
Fibonacci274.1 275.73 278.37271.45 268.81 267.18 264.53
Camarilla270.75 271.39 272.02271.45 269.49 268.85 268.22

Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.

Moving Averages
Days
5270.1
10266.28
20267.12
50276.16
100258.37
200252.06

Returns

Price Performance
1 Week4.70%
1 Month
-1.69%
3 Months18.00%
YTD4.34%
1 Year18.91%
3 Years14.98%

Financialsin million $

Peers

NamePrice ($)Change%M.Cap(Billion $)TTM PETTM EPSDY52 wk high/lowTechnical Rating
J&J175.16-0.24457.8517.629.942.77186.69/155.72-0.35Bearish
Eli Lilly352.750.83335.1841.558.491.21375.25/231.87-2.30Very Bearish
AbbVie159.64-1.25282.2711.7413.604.20175.91/128.26-2.12Bullish
Merck & Co110.810.39280.8214.467.663.20115.49/72.881.75Bullish
Pfizer47.57-1.69267.257.256.573.6657.43/41.45-7.86Bearish

About the company

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.